Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Medication patches are available in a limited number of dosage strengths. Occasionally, some patients require a different dosage of a medication than the dosages commercially available in patch ...

Discover Agile Therapeutics' patented transdermal drug delivery device, designed to reduce skin irritation and enhance stability for effective seven-day wear.

The on-body injector administers Starton’s cancer drug STAR-LLD continuously and at a low dose through the skin.

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent ...

The absence of any discernible untoward effect of ultrasound is relevant, because many transdermal patches in wide clinical use (for example, estradiol) cause severe skin irritation 19.

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

Global Transdermal Medical Patch Market is valued at approximately USD 7.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2024-2032.

Menopausal hormone therapy reduced the risk for psychosis relapse by 16% in women with schizophrenia or schizoaffective ...

MedPharm, a global topical and transdermal Contract Development and Manufacturing Organization ("CDMO"), today announced Mr.

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven ...